1:15 PM
 | 
Feb 13, 2019
 |  BC Extra  |  Company News

IBM, Broad to use AI to improve CV genetic risk prediction

The Broad Institute of MIT and Harvard and the IBM Watson Health business of IBM Corp. (NYSE:IBM) have teamed up to develop artificial intelligence algorithms to improve the predictive power of polygenic scoring of cardiovascular disease risk. The AI models will integrate and analyze genetic risk factors within a patient's genome, electronic health records and biomarker data to help clinicians better predict the onset of CV conditions such as heart attacks.

CV disease is steeped in complexity because a variety of genetic, environmental and lifestyle factors can make someone more susceptible, said Jianying Hu, an IBM Healthcare and Lifesciences Research Fellow.

"AI technology has the potential to help researchers,...

Read the full 523 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >